[HTML][HTML] A roadmap towards a human-centric safety assessment of advanced therapy medicinal products

HT Chien, VC de Leeuw, JCJ van Esterik… - Regulatory Toxicology …, 2024 - Elsevier
Advanced therapy medicinal products (ATMPs) are among the most complex pharmaceuticals
with high human specificity. Species differences severely limit the clinical relevance of in …

Regulatory aspects for approval of advanced therapy medicinal products in the EU

S Fürst-Ladani, A Bührer, W Fürst… - Drug Delivery and …, 2023 - Springer
Advanced therapy medicinal products (ATMPs) are a group of … biological medicines that
offer novel therapeutic opportunities … therapy medicinal products (GTMPs), somatic cell therapy

The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the WHO Global Benchmarking Tool standards

J Shi, X Chen, H Hu, COL Ung - Cytotherapy, 2024 - Elsevier
Advanced therapy medicinal products (ATMPs) are rapidly evolving to offer new treatment
options. The scientific, technical and clinical complexities subject drugtechnology evaluation

[HTML][HTML] Real world data in health technology assessment of complex health technologies

MA Hogervorst, J Pontén, RA Vreman… - Frontiers in …, 2022 - frontiersin.org
… Novel, complex treatment strategies such as health technologies with concomitant genetic
testing, advanced therapy medicinal products (ATMPs) or the assessment of sequences of …

… pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and …

R Tarricone, H Banks, O Ciani, W Brouwer… - … Review of Medical …, 2023 - Taylor & Francis
Full article: An accelerated access pathway for innovative high-risk medical devices under
the new European Union Medical Devices and health technology assessment regulations? …

[PDF][PDF] Commercialisation of Advanced Therapies

J Mansnérus - … Regulation on Advanced Therapy Medical Products …, 2016 - helda.helsinki.fi
… , improve safety and access to advanced therapies include: facilitating R&D by adaptive,
risk… , regulatory authorities as well as health technology assessment bodies and payers alike. …

Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries

DGM Coppens, H Gardarsdottir, MLD Bruin… - … Medicine, 2020 - Taylor & Francis
… The Hospital Exemption (HE) was enacted to accommodate manufacturing of advanced
therapy medicinal products (ATMPs) for treatment purposes. However, how its implementation …

[HTML][HTML] Surrogate endpoints in health technology assessment: an international review of methodological guidelines

B Grigore, O Ciani, F Dams, C Federici, S de Groot… - …, 2020 - Springer
health technologies Our survey shows that many international health technology assessment
(HTA) agencies currently lack detailed guidance for the evaluation of health technologies

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models

M Pochopień, E Paterak, E Clay, J Janik… - … Market Access & Health …, 2021 - mdpi.com
therapies are a novel treatment approach, they may be assessed by health technology
assessment (… A standardised approach to gene therapies has not been elaborated yet. Moreover, …

[HTML][HTML] Promoting innovation while controlling cost: the UK's approach to health technology assessment

M Anderson, M Drummond, D Taylor, A McGuire… - Health Policy, 2022 - Elsevier
… ’ technologies such as advanced therapy medicinal products (ATMPs), defined as “medicines
for … Emerging developments in immunotherapy in cancer and gene therapy, will lead to an …